메뉴 건너뛰기




Volumn 27, Issue 3, 2010, Pages

Sibutramine: Gone, but not forgotten

Author keywords

[No Author keywords available]

Indexed keywords

AMFEPRAMONE; ANTIOBESITY AGENT; CONTRAVE; DAPAGLIFLOZIN; EMPATIC; LIRAGLUTIDE; LORCASERIN; PHENTERMINE; PLACEBO; RIMONABANT; SIBUTRAMINE; TESOFENSINE; TETRAHYDROLIPSTATIN; TORCETRAPIB; UNCLASSIFIED DRUG;

EID: 77952787196     PISSN: 13578170     EISSN: 1528252X     Source Type: Journal    
DOI: 10.1002/pdi.1453     Document Type: Short Survey
Times cited : (2)

References (14)
  • 1
    • 0034516930 scopus 로고    scopus 로고
    • Effect of sibutramine on weight maintenance after weight loss: A randomised trial
    • STORM Study Group. Sibutramine trial of obesity reduction and maintenance
    • James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine trial of obesity reduction and maintenance. Lancet 2000; 356: 2119-2125.
    • (2000) Lancet , vol.356 , pp. 2119-2125
    • James, W.P.1    Astrup, A.2    Finer, N.3
  • 2
    • 0035913584 scopus 로고    scopus 로고
    • Long-term weight loss with sibutramine: A randomized controlled trial
    • Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001; 286: 1331-1339. (Pubitemid 33015524)
    • (2001) Journal of the American Medical Association , vol.286 , Issue.11 , pp. 1331-1339
    • Wirth, A.1    Krause, J.2
  • 3
    • 0034520443 scopus 로고    scopus 로고
    • Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: A randomised, double-blind, placebo-controlled study
    • DOI 10.1046/j.1463-1326.2000.00071.x
    • Finer N, Bloom SR, Frost GS, et al. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab 2000; 2: 105-112. (Pubitemid 33072165)
    • (2000) Diabetes, Obesity and Metabolism , vol.2 , Issue.2 , pp. 105-112
    • Finer, N.1    Bloom, S.R.2    Frost, G.S.3    Banks, L.M.4    Griffiths, J.5
  • 4
    • 0038510366 scopus 로고    scopus 로고
    • A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin
    • Multicenter Sibutramine Study Group
    • McNulty SJ, Ur E, Williams G; Multicenter Sibutramine Study Group. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 2003; 26: 125-131.
    • (2003) Diabetes Care , vol.26 , pp. 125-131
    • McNulty, S.J.1    Ur, E.2    Williams, G.3
  • 5
    • 0008084861 scopus 로고    scopus 로고
    • Weight loss produced by sibutramine: A metaanalysis
    • Astrup A, Chong E. Weight loss produced by sibutramine: a metaanalysis. Int J Obes Relat Metab Disord 2001; 25(Suppl 2): S104.
    • (2001) Int J Obes Relat Metab Disord , vol.25 , Issue.SUPPL. 2
    • Astrup, A.1    Chong, E.2
  • 6
    • 0034516930 scopus 로고    scopus 로고
    • Efficacy of sibutramine on weight maintenance after weight loss: A randomised trial
    • The STORM Study Group
    • James WS, Astrup A, Finer N, et al. Efficacy of sibutramine on weight maintenance after weight loss: a randomised trial: The STORM Study Group. Lancet 2000; 356: 2119-2125.
    • (2000) Lancet , vol.356 , pp. 2119-2125
    • James, W.S.1    Astrup, A.2    Finer, N.3
  • 7
    • 0036733520 scopus 로고    scopus 로고
    • Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction
    • Zannad F, Gille B, Grentzinger A, et al. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am Heart J 2002; 144: 508-515.
    • (2002) Am Heart J , vol.144 , pp. 508-515
    • Zannad, F.1    Gille, B.2    Grentzinger, A.3
  • 9
    • 27744466523 scopus 로고    scopus 로고
    • The SCOUT study: Risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients
    • James WPT. The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients. Eur Heart J Suppl 2005; 7(Suppl L): L44-L48.
    • (2005) Eur Heart J Suppl , vol.7 , Issue.SUPPL. L
    • James, W.P.T.1
  • 10
    • 77952756208 scopus 로고    scopus 로고
    • Does the risk profile of patients with cardiovascular disease and/or diabetes modify initial response to treatment with sibutramine? A preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial
    • on behalf of the SCOUT Investigators. Abstract T2:PS:80 available at
    • Caterson I, Sharma AM, Coutinho W, et al.; on behalf of the SCOUT Investigators. Does the risk profile of patients with cardiovascular disease and/or diabetes modify initial response to treatment with sibutramine? A preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial. Int J Obes 2008; 32(Suppl 1s): S100, Abstract T2:PS:80 (available at: www.nature.com/ijo/journal/v32/n1s/pdf/ijo200847a.pdf).
    • (2008) Int J Obes , vol.32 , Issue.SUPPL. 1S
    • Caterson, I.1    Sharma, A.M.2    Coutinho, W.3
  • 11
    • 65549167028 scopus 로고    scopus 로고
    • The obesity paradox, weight loss, and coronary disease
    • 12 Aug [epub ahead of print]
    • Lavie CJ, Milani RV, Artham SM, et al. The obesity paradox, weight loss, and coronary disease. Am J Med 12 Aug 2009 [epub ahead of print].
    • (2009) Am J Med
    • Lavie, C.J.1    Milani, R.V.2    Artham, S.M.3
  • 12
    • 67651096062 scopus 로고    scopus 로고
    • Explaining the obesity paradox: Cardiovascular risk, weight change, and mortality during long-term follow-up in men
    • Strandberg T, Strandberg A, Salomaa V, et al. Explaining the obesity paradox: cardiovascular risk, weight change, and mortality during long-term follow-up in men. Eur Heart J 2009; 30: 1720-1727.
    • (2009) Eur Heart J , vol.30 , pp. 1720-1727
    • Strandberg, T.1    Strandberg, A.2    Salomaa, V.3
  • 13
    • 75749148775 scopus 로고    scopus 로고
    • Obesity paradox and cardiorespiratory fitness in 12,417 male veterans aged 40 to 70 years
    • McAuley PA, Kokkinos PF, Oliveira RB, et al. Obesity paradox and cardiorespiratory fitness in 12,417 male veterans aged 40 to 70 years. Mayo Clin Proc 2010; 85(2): 115-121.
    • (2010) Mayo Clin Proc , vol.85 , Issue.2 , pp. 115-121
    • McAuley, P.A.1    Kokkinos, P.F.2    Oliveira, R.B.3
  • 14
    • 77649154704 scopus 로고    scopus 로고
    • Obesity paradox or reverse epidemiology
    • Epub 23 Feb 2010
    • Dorner TE, Rieder A. Obesity paradox or reverse epidemiology. Dtsch Med Wochenschr 2010; 135(9): 413-418. [Epub 23 Feb 2010.]
    • (2010) Dtsch Med Wochenschr , vol.135 , Issue.9 , pp. 413-418
    • Dorner, T.E.1    Rieder, A.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.